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The idea that  the immune  response to an antigen  (Ag) ~ can be regulated by 
an idiotype (Id)-antiidiotype network was first proposed by Jerne (1).  Id located 
on or close to the Ag-binding  site of both antibody molecules and  lymphocyte 
Ag receptors are components of this network. Numerous studies have implicated 
Id networks in regulating the immune response to a large variety of haptens and 
protein or carbohydrate Ag (reviewed in 2 and 3). The injection ofanti-Id before 
Ag exposure has resulted in either suppression of the Id  + Ag-binding molecules, 
or increased  Id expression and Ag-binding activity. Recent studies (4-11) have 
indicated  that anti-Id  may be useful in inducing  protective immunity against a 
wide variety of infectious agents, and have suggested the potential of anti-Id as 
vaccine candidates (12,  13). Alternatively, anti-Id injection before exposure with 
another  infectious  agent  resulted  in  an  apparent  suppression  of the  immune 
response, which manifested itself in an increase in pathogenicity of the agent for 
the host (14). 
The use ofanti-ld in the treatment of cancer has primarily focused on lymphoid 
tumors  (reviewed  in  15  and  16).  In  these  studies,  cell  surface  Ig  present  on 
neoplastic B lymphoid cells represents the Id, and suitable anti-Id could eliminate 
much  or  all  of the  tumor,  with  negligible  effects on  residual  normal  tissues. 
Injection of mice with anti-Id that appears to mimic the tumor Ag structure has 
been  reported  to  induce  antitumor  immunity  in  human  melanoma  (17)  and 
mammary  adenocarcinomas  (18).  Alternatively,  anti-Id  generated  against  sup- 
pressor T  lymphocyte receptors was also capable of reducing the in vivo tumor 
growth of a  mastocytoma (19), whereas another report (20) indicated that anti- 
Id suppressed tumor rejection to fibrosarcomas when produced against T  lym- 
phocyte  clones.  A  recent  study  (21)  has  implicated  anti-Id,  produced  when 
humans were injected with mouse monoclonal antibodies (mAb) against gastroin- 
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testinal cancer cells,  in the clinical improvement and longer remission of these 
patients with colorectal carcinoma. Together, these data indicate that Id networks 
may play some integral immunological role in the formation of tumors. 
Simian virus 40 (SV40) is an oncogenic DNA virus that induces tumors in vivo 
when inoculated into newborn  hamsters, and transforms cells in  vitro from a 
variety of species, including rodents, primates, and humans. Rodent cells trans- 
formed by  SV40  in  vitro  will  frequently form  tumors  in  hamsters and  mice 
(reviewed in  22).  Cells that have been  transformed by SV40  express a  virally 
encoded tumor antigen (T-Ag). T-Ag is predominantly localized in the nucleus 
of transformed cells;  however,  a  small  fraction of T-Ag is  found on  the  cell 
surface (23-27).  Mice immunized against T-Ag are protected from challenge by 
syngeneic SV40  tumor cells  (28-31,  reviewed in 32).  Thus, the SV40  T-Ag is 
associated with the induction of tumor immunity. 
In this report,  we generate and characterize rabbit anti-Id reagents against 
mouse mAb to the carboxyl and amino terminal epitopes of SV40 T-Ag, and to 
a cellular protein, designated p53 (33-35), that is intimately associated with T- 
Ag on the surface of transformed cells (36,  37).  These anti-Id reagents each 
recognized antibody-combining  site-related, private Id determinants. Treatment 
of BALB/c  mice  with  a  pool  of anti-Id  generated  against  mAb  to  both  the 
carboxyl and amino termini of SV40 T-Ag before challenge with a tumorigenic 
dose  of SV40-transformed  cells  partially suppressed  tumor  growth.  In  some 
instances,  this  suppression  was complete,  since  several  of the pooled anti-Id- 
treated mice failed to develop any detectable tumors after challenge, whereas 
100% of the control groups of mice developed tumors. The implications of these 
observations with  regard  to  Id  networks and  SV40  tumor  induction will  be 
discussed. 
Materials and Methods 
Mice.  Adult female  BALB/c mice were purchased  at 6-8  wk,  from Charles  River 
Breeding Laboratories,  Inc., Wilmington, MA. 
Virus and Cell Lines.  The Baylor reference strain of wild-type SV40 (38) was grown 
and assayed as previously described (39). The transplantable  SV40-transformed  BALB/c 
mouse  cell lines mKSA  (40, 41)  and  VLM  (41) were  used  for  intraperitoneal  and 
intradermal tumor cell challenges, respectively. The SV40-transformed hamster cell line, 
HaAsc (24), and the SV40-transformed  mouse cell line, 3T3/SV-1/10 (42), were used for 
T-Ag and p53 purification.  All SV40-transformed  cell lines were cultured in Dulbecco's 
modified minimal essential medium (Gibco Laboratories, Grand Island, NY) supplemented 
with  10%  fetal bovine serum  (Gibco Laboratories),  0.3% sodium bicarbonate,  and 25 
ug/ml gentamicin sulfate (Schering Corp., Bloomfield, N  J). 
Purification  of SV40  TAg and p53 Cellular Protein.  T-Ag and p53  were purified by 
immunoaffinity  chromatography, mAb PAb419 was covalently crosslinked to protein A- 
Sepharose  (Pharmacia  Fine  Chemicals,  Piscataway, NJ)  according  to  the  method of 
Schneider and coworkers (43). The preparation containing only T-Ag was derived from 
extracts of the SV40-transformed  hamster cell line, HaAsc (24), which contains very low 
levels of p53.  The preparation containing T-Ag and p53 was obtained from the SV40- 
transformed mouse cell line, 3T3/SV-1/10 (33), which contains very high levels of p53. 
Thus, p53 was purified from the same cells, by virtue of its association with T-Ag. Briefly, 
T-Ag present in detergent extracts of tissue culture cells was bound to the affinity matrix 
during an overnight incubation,  with shaking. A column was prepared from the T-Ag- 
containing affinity matrix, and T-Ag was eluted using 10 mM Tris-NaOH (pH 11.0) and 
100 mM NaCI. Fractions were collected in an equal volume of 50 mM Tris-HCl (pH 7.0) 1434  ANTIIDIOTYPES MODULATE TUMOR  FORMATION 
and  100 mM NaCI to rapidly neutralize the high-pH elution buffer. The peak fractions 
were pooled and concentrated in Centricon-30 tubes (Amicon Corp., Danvers, MA). 
Antibodies and Their Purification.  The following mAb recognize SV40 T-Ag: PAb 405, 
416,419,423, and 430, and were the gifts of Dr. E. Harlow. mAb PAb 421 and HD 200 
recognize  p53,  and  were  gifts  from  E.  Hariow  and  A.  DeLeo,  respectively.  These 
antibodies  have been  described  in  detail  elsewhere  (44,  45),  and  their  specificities  are 
given in  Table  I.  mAb A-l,  A-2,  W-l,  and  W-2,  which recognize  hepatitis  B  surface 
antigen (HBsAg) were generated in this laboratory (46). All hybrid clones were passaged 
in ascites form by intraperitoneal  injection of 1-5 x  106 hybrid cells into pristane-primed 
BALB/c mice. 
Mouse ascites fluid was delipidated at 4°C by the addition of manganese chloride to a 
final concentration of 2.5 raM. After centrifugation at 2,000 g to remove lipids,  18-20% 
(wt/vol)  sodium  sulfate  was  added,  at  room  temperature.  The  resulting  precipitate, 
containing the globulin fractions, was suspended in 0.16 M borate buffer (pH 8.2), and 
was  further  fractionated  by  molecular  sieve  chromatography  on  a  Sephadex  G-200 
(Pharmacia  Fine  Chemicals) column  equilibrated  in  borate buffer.  The  IgG-containing 
peak was concentrated, and the amount of protein was determined spectrophotometrically 
by using an extinction  coefficient of 14 for a  1%  preparation  at  280  nm.  IgG was also 
purified from BALB/c mouse serum using similar methods. To insure the purity of the 
IgG Id preparations,  PAb 419  and  421  were recycled over Sephadex  G-200  columns, 
while  PAb 405  and  HD  200  were  further  purified  by preparative  isoelectric  focusing 
using an LKB electrofocusing apparatus in a sucrose ampholyte gradient (with a pH range 
of 3.0-9.5), according to the manufacturer's specifications. The sucrose was removed by 
dialysis against borate buffer. 
lmmunoadsorbents for Id and Anti-Id Reagents.  Individual IgG antibody preparations 
from normal  BALB/c mouse  sera,  PAb 405,  419,  421,  and  HD  200  were  covalently 
coupled to CNBr-activated Sepharose 4  B at a  concentration of 3  mg/ml of Sepharose. 
Affinity-purified IgG rabbit anti-Id preparations to PAb 405, 419, 421, and HD 200 were 
individually coupled to CNBr-activated Sepharose 4  B at a concentration of 1 mg/ml of 
Sepharose. 
Preparation ofAnti-Id Antisera.  The preparation of anti-Id in rabbits and its subsequent 
affinity purification  have been described  previously in  detail  (47-49).  Briefly,  2  mg of 
IgG anti-SV40  T-Ag or anti-p53  from four separate  clones (PAb 405,  PAb 419,  PAb 
421, and  HD  200) was emulsified  in complete  Freund's adjuvant and injected  into the 
footpads of at  least  two New Zealand  White  rabbits.  Each rabbit  received at  least  four 
biweekly injections before obtaining antiserum. The immune rabbit antisera were repeat- 
edly adsorbed on a Sepharose  4  B column conjugated with normal BALB/c mouse IgG 
until all  detectable reactivity with isotype and allotype determinants were removed. The 
presence  of antiisotypic and  antiallotypic  antibody was determined  by a  direct-binding 
TABLE  I 
Summary of Specificities of mAb Used as Inhibitors 
Reactions 
in Id-Anti-Id 
Designation  Antibody class  Specificity  Reference 
PAb 405  lgG 1  Anti-T-Ag  44 
PAb 416  IgG2a  Anti-T-Ag  44 
PAb 419  IgG2a  Anti-T-Ag  44 
PAb 421  IgG2a  Anti-p53  44 
PAb 423  IgGl  Anti-T-Ag  44 
PAb 430  IgG3  Anti-T-Ag  44 
HD 200  IgG2a  Anti-p53  45 
A- 1  IgG 1  Anti-HBsAg  46 
A-2  IgG 1  Anti-HBsAg  46 
W- 1  IgG 1  Anti-HBsAg  46 
W-2  IgG l  Anti-H BsAg  46 KENNEDY  ET  AL.  1435 
radioimmunoassay  (RIA) (see  below).  Potential  shared  determinants  were  removed by 
further adsorption ofantisera over anti-T-Ag or anti-p53 mAb immunoadsorbent columns 
that were unrelated  to the  rabbit  immunogen.  Following the removal of all detectable 
antiisotype  and  antiallotype  reactivity,  the  rabbit  anti-Id  preparations  were  affinity- 
purified on Sepharose 4 B columns containing the respective mAb Id preparations.  The 
elution  of affinity-purified  rabbit  anti-Id  was  performed  with  1  M  acetic  acid,  using 
methods previously described in detail (7,  49).  The concentration  of rabbit anti-Id was 
determined spectrophotometrically, using an extinction coefficient of 15 for a  1% prepa- 
ration. 
Preparation of Affinity-purified Id.  Ascites fluid  from the  four  Id preparations  were 
delipidated and salt-fractioned as descritted above, and dialyzed overnight at 4 °C against 
borate buffer.  The individual  Id preparations  were then adsorbed on affinity columns 
containing their respective rabbit anti-Id. The affinity columns were washed with excess 
borate buffer until no detectable protein was present  in the eluent, and affinity-purified 
Id preparations were then eluted with  1 M acetic acid. The protein-containing fractions 
were pooled,  neutralized,  and dialyzed overnight at  4°C in borate buffer.  The affinity 
purification is similar to methods previously described (7, 49). These idiotype preparations 
were concentrated, and the amount of protein was determined  spectrophotometrically. 
Anti-SV40  T-Ag or p53  activity  was  determined  by immunoprecipitation  or indirect 
immunofluorescence, as described below. The affinity-purified Id preparations were used 
solely for the in vivo modulation experiments on SV40 tumor induction. 
Assays for Antibody Activity Against SV40  TAg and p53.  Sera  from mice immunized 
with rabbit anti-SV40 T-Ag and p53 Id were assayed for anti-T-Ag and anti-p53 activity 
by immunofluorescence and  immunoprecipitation.  Immunofluorescence assays  for nu- 
clear  T-Ag  or  p53  were  performed  on  acetone-fixed  monolayers  of VLM  cells,  as 
previously described (50), using serial twofold dilutions of the mouse serum, followed by 
fluorescent-conjugated rabbit anti-mouse  IgG (Cappel  Laboratories, Cochranville,  PA). 
1  1  w"  35  .....  Detergent extracts of VLM cells  abe ed  lth [  S]methlomne were Immunopreclpltated 
with the different mouse sera and analyzed for T-Ag and p53 on sodium dodecyl sulfate 
(SDS)-polyacrylamide gels as previously described (24). 
Assays for Detecting Anti-ld Activity: Binding Assays.  A solid-phase RIA was used for the 
binding analysis of the anti-Id antisera (47-49). Briefly, 50 ~1 containing 200 ng of mouse 
IgG prepared  from mAb-containing ascites fluid or BALB/c mouse serum were coated 
onto the wells of flat-bottomed microtiter polyvinyl plates for 8 h at 4°C. After blocking 
nonspecific sites with  1% bovine serum albumin, 50 #1 of various dilutions of rabbit anti- 
Id antisera or concentrations of affinity-purified anti-Id were added, and incubated for 1 
h at 25°C. The microtiter plates were washed with a 0.01% Tween 20 phosphate buffered 
saline and  50/~l  of a  reagent  containing  100,000  cpm of a  ~25I-labeled  goat anti-rabbit 
gamma globulin (GARGG) were added. The preparation and chloramine-T iodination of 
GARGG are  described  elsewhere  (47).  After incubation  for  1 h  at  25°C,  the  residual 
radioactivity was removed, and the plates were washed. The wells of the microtiter plates 
were cut out, and bound radioactivity was counted in an automatic gamma counter. The 
binding curves generated were expressed as cpm 125I-labeled  GARGG bound vs. concen- 
tration of anti-Id. 
Inhibition Assays.  A solid-phase RIA with IgG mAb used as inhibitors was performed 
according to  the  previously described  methods  (45).  Briefly,  equal  volumes  of various 
inhibitors and anti-Id, used at a concentration corresponding to the linear portion of the 
binding curve,  were  preincubated  for 4  h  at  4°C  before the  addition  of 50 /A of the 
inhibitor-anti-Id complex to the Id-coated wells. This assay was then performed similarly 
to that described above for direct binding.  The percent  inhibition  was calculated from 
the formula: Percent inhibition =  1 -  [(cpm bound with inhibitor)/(cpm bound without 
inhibitor)]  x  100.  The  percent  inhibition  was determined  from the  mean  of triplicate 
values. 
To ascertain whether purified SV40 T-Ag and p53 would inhibit the Id-anti-Id binding, 
a modification was made in the inhibition assay. The microtiter wells were coated with 50 
~1 of a concentration of anti-Id corresponding to the linear portion of the binding curve. 1436  ANTIID1OTYPES  MODULATE  TUMOR  FORMATION 
After adding  1% bovine serum albumin to block nonspecific sites, we added 50 #1 of a 
solution containing equal volumes of various concentrations of T-Ag or p53 and 50,000 
cpm of ~25I-labeled  Id  that  had  been  previously preincubated  for 4  h  at  4°C.  After 
incubating  for  1  h  at  25°C,  removing residual  radioactivity,  washing  the  plates,  and 
counting were performed as described. The percent inhibition of binding was calculated 
from the formula described above. 
Assay for Detecting Anti-anti-Id (Ab3) Activity.  This assay is similar to that described 
above for the inhibition of the Id-anti-Id reaction, except that mouse sera obtained from 
anti-Id-treated  mice  were  used  to  inhibit  the  solid-phase  RIA.  Radioactively  labeled 
GARGG was used to detect the inhibition of the anti-Id binding to its respective Id. 
In Vivo Administration  of ld and Anti-Id Preparations.  BALB/c mice were given intra- 
peritoneal injections of either affinity-purified Id or anti-Id, as an alum precipitate at pH 
7.0.  Control antibodies were affinity-purified rabbit anti-Id that recognized a  common 
human Id on antibodies against HBsAg. This preparation was generated by adsorptions 
similar to those described for the anti-SV40 T-Ag Id preparations. The specificity of this 
reagent has been described elsewhere (7,  47).  Mice received three injections of 50  tsg 
alum-precipitated  anti-Id,  every  10  d,  and  serum  was  obtained  7  d  after  the  third 
immunization. Serum obtained from each mouse before any immunization served as a 
negative control. In addition, groups of mice received three injections of 50 ~g of either 
anti-Id or Id preparations every 10 d, and were challenged with a  tumorigenic dose of 
SV40-transformed cells (VLM or mKSA) 7 d  after the final immunization. The tumor 
cell inoculum corresponded to a dose where  100% of untreated animals would develop 
tumors. The tumorigenic immunization was given either intradermally, behind the neck 
of the  animals (VLM cells),  or intraperitoneally  (mKSA cells).  The VLM  tumors  that 
developed from the intradermal injection were measured by calipers, and expressed as 
the size of the tumor diameter. Tumor growth in mice receiving mKSA ceils intraperito- 
neally was determined by the survival time of the animals. Numerous pilot experiments 
were performed to establish the optimal parameters with regard to concentrations of the 
antibody preparations, dose of the SV40 tumor cells, and time interval between injections 
of antibodies and tumor cells. 
Statistical Methods.  The levels of significance (P values) were obtained using the two- 
tailed student's t test on the mean survival time of each treatment group of mice. 
Results and  Discussion 
Rabbit Antisera  to  SV40  mAb  Recognize  Private Id Determinants.  The  anti-Id 
nature of four different rabbit antisera was demonstrated by the binding curves 
shown in Fig.  1. Two rabbit antisera, anti-419 Id and anti-405 ld were generated 
against  mAb  that  recognized  SV40  T-Ag.  These  antisera  bound  only  their 
respective  monoclonal  Id  preparation,  and  failed  to  significantly  bind  to  IgG 
from  other  SV40  T-Ag  mAb,  and  also  IgG  prepared  from  normal  BALB/c 
mouse serum,  mAb against p53,  and  mAb against  HBsAg (anti-HBs) (data not 
shown).  In this regard, at a concentration  of 400 ng, anti-419  Id bound  30,100 
cpm with the 419 Id, while only 150-300  cpm were bound with all other mouse 
IgG preparations (Fig.  1 A). Similar results are illustrated by the binding curves 
generated  with  anti-405  Id  (Fig.  1B).  Two  other  antisera  were  produced  by 
immunizing rabbits with  IgG obtained from two p53  mAb. Again, anti-421  Id 
and  anti-HD  200  Id  demonstrated  the  ability  to  bind  only their  respective Id 
preparations (Fig.  1, C and D). 
In  the  next  series  of experiments,  the  individual  Id-anti-Id  reactions  were 
examined by inhibition analysis to further determine whether the rabbit anti-Id 
recognized determinants associated only with the  immunizing IgG mAb prepa- KENNEDY  ET  AL.  1437 
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FIGURE  1.  Binding  curves of anti-ld with IgG isolated from normal BALB/c serum (n), from 
ascites fluid containing  the following antibodies against SV40 T-Ag; 419 (O), 405 (Q), 421 (11), 
and HD 200 (~). The following rabbit anti-Id were used: (A) anti-419; (B) anti-405; (C) anti- 
421; (D) anti-HD 200. Each point represents the mean of triplicate values. 
TABLE  II 
Inhibition of Binding of Rabbit Anti-Id to Their Respective Id by 
Various IgG Inhibitors 
HD 200 
Inhibitor*  405 Id-anti-  419 Id-anti-  421 Id-  Id-anti-HD 
405  419  anti-421  2OO 
% 
PAb 405  99*  6  1  5 
PAb 416  0  4  1  6 
PAb 419  3  100  0  7 
PAb 421  0  6  96  2 
PAb 423  0  8  2  2 
PAb 430  0  3  1  9 
HD 200  4  4  2  98 
A-1  1  7  0  3 
A-2  1  4  2  3 
W-1  0  2  0  5 
W-2  0  5  0  4 
* All inhibitors were used at a final concentration of 5 #g. 
* Represents  the mean percent inhibition  of binding obtained from trip- 
licate values. 
rations. A  summary of the characteristics and specificity of all the mAb used in 
the  inhibition analysis is  given  in  Table  I.  Based  on  the  ability to  block  the 
binding of the anti-Id to the respective Id, only the specific IgG preparation used 
as  the  immunogen  was  capable of significantly (>95%)  inhibiting the  reaction 
(Table II). At a  concentration of 5 #g, normal mouse IgG and IgG purified from 
various  non-Id  mAb  did  not  significantly inhibit any  of  the  four  Id-anti-Id 
reactions. Inhibition values from  1 1  different IgG preparations ranged from 0 1438  ANTIIDIOTYPES  MODULATE  TUMOR  FORMATION 
to 9%. The  inhibition  curves obtained using the  homologous Id to inhibit  the 
various Id-anti-Id  reactions are depicted in Fig. 2. The inhibitor concentration 
that gave 50% inhibition 05o) of the 419 Id-anti-419 Id reaction was 10 ng (Fig. 
2A). The I50 values for 405 Id-anti-405  Id, 421  Id-anti-421  Id, and HD 200 
Id-anti-HD 200 Id were 12 ng, 9.6 ng, and 5 ng, respectively (Fig. 2, B, C, and 
D).  Based on  these data,  it was apparent  that  each  of the  four rabbit antisera 
detected  a  unique  determinant  present  on  only  the  immunizing  IgG  mAb 
preparation. 
Inhibition of ld-binding Anti-Id by Purified SV40 TAg and p53 Protein Prepara- 
tions.  To ascertain whether the determinants recognized by the various Id-anti- 
Id reactions were associated with the antibody-combining site of the Id, purified 
preparations  containing either T-Ag or both T-Ag and p53 as a complex were 
used as inhibitors.  The reactions of 421  Id-anti-421  Id and  HD200 Id-anti- 
HD 200 Id were inhibited only by the T-Ag-p53 complex preparation  and not 
by purified T-Ag alone (Table III). At a total protein concentration of 2 gg, the 
T-Ag-p53 preparation  inhibited 421  Id-anti-421  Id and HD 200 Id-anti-HD 
200 Id reactions by 53% and 36%, respectively. These data indicate that the two 
anti-Id preparations recognized determinants associated with the antibody-cam- 
FIGURE  2. 
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Inhibition curves of anti-Id binding to its respective ld, using the following IgG 
preparations as inhibitors: normal BALB/c serum (I-q); ascites fluid from 419 (O); 405 (O); 421 
(In); and HD 200  (A)- The following rabbit anti-Id were used: (A) anti-419; (B) anti-405; (C) 
anti-421; (D) anti-HD 200. Each point represents the mean of triplicate values. 
TABLE  III 
Inhibition of Binding of Anti-ld to Id by SV40 T-Ag and T-Ag/p53-complex Preparations 
HD 200  421  Id-  419  Id-  405-1d-  Inhibitor  Concentration  Id-anti-  anti-421  anti-419  anti-405  HD 200 
ug  % 
BSA  1,000  0*  0  0  0 
Ovalbumin  l 0,000  0  0  0  0 
SV40 T-ag/p53 complex  2  53  36  32  31 
0.4  43  19  7  20 
SV40 T-ag  2  0  2  32  93 
0.4  1  0  26  88 
* Mean of triplicate values. KENNEDY  ET  AL.  1439 
bining site of anti-p53 protein mAb. Similarly, the two anti-Id generated to SV40 
T-Ag mAb also appeared  to recognize  the antibody-combining site.  Inhibition 
of 419 Id-anti-419  Id and 405 Id-anti-405  Id reaction was obtained with both 
the T-Ag-p53  complex-containing preparation  and with purified T-Ag (Table 
III).  In  the 405  Id-anti-405  Id reaction,  the purified  T-Ag was a  much more 
efficient inhibitor (2 tag inhibited 93%) compared with the T-Ag-p53-containing 
preparation  (2 tag inhibited  31%).  Conversely, both preparations  were equally 
efficient as inhibitors  of the  419  Id-anti-419  Id reaction.  The  reason for the 
difference in inhibitor capacity of the antigen preparations in the two SV40 T- 
Ag Id-anti-Id reactions is not known. However, the possibility exists that during 
affinity purification and elution with high pH from an affinity column containing 
IgG purified  from  419,  antigenic  determinants  associated with  the amino  ter- 
minal  portion  of T-Ag,  which  are  bound  by  419,  were  more  labile.  Thus, 
denaturation of epitopes associated with the 419, SV40 T-Ag-binding site might 
explain  the  apparent  differences  in  inhibitor  capacity  of the  purified  T-Ag 
preparation  to inhibit the two Id-anti-Id  reactions.  Alternatively,  419 IgG may 
have leeched off the affinity column and contaminated the T-ag preparation.  In 
this instance, some of determinants recognized by 419 Id may have been bound 
by contaminating  419 and diminished  the capacity of the T-Ag preparation  to 
inhibit  the  419  Id-anti-419  Id.  This  possibility seems  less likely,  since  no  Ig 
heavy or light chain contamination was seen in silver-stained SDS-polyacrylamide 
gels of the  purified  T-Ag  (data  not  shown).  Thus,  any  contamination  of 419 
from the affinity column would be minimal. 
Based on the binding and  inhibition  studies,  each  Id-anti-Id  reaction recog- 
nized  unique  Id  determinants  associated,  at  least  in  part,  with  the  antibody- 
combining site of the immunized Id preparation.  These data indicate that these 
anti-Id reagents do indeed detect Id determinants. 
Numerous  studies had  previously reported  the  use of anti-Id  in  modulating 
the immune response to both infectious agents (4-11) and tumors (17-21). We 
decided to use the anti-Id reagents against SV40 T-Ag and p53 in an attempt to 
modulate the immune response to SV40 tumor induction  in  vivo. We selected 
BALB/c  mice  as  the  animal  of choice  for  these  studies  because  tumorigenic, 
SV40-transformed BALB/c cells lines were available, and because the Id prepa- 
ration was of BALB/c origin.  In our initial studies, we selected a dose of SV40- 
transformed  cells that  would induce  visible tumors in  100%  of the  inoculated 
mice after 21  d. The route of inoculating  10 4 SV40 tumor cells (VLM cells) was 
intradermal,  behind the neck. All anti-Id immunizations were given intraperito- 
neally as an alum  precipitate,  since we had previously demonstrated  that  alum 
adsorption  of anti-Id  against  HBsAg induced  high  titers of antibodies in  mice 
(7). 
Effect of Anti-Id  Immunization  on  SV40  Tumor  Induction.  In  our first  set  of 
experiments,  nine  groups of eight mice each were given three injections of 50 
ug of anti-Id,  10 d  apart,  then challenged  with  104 VLM tumor cells 7 d  after 
the final injections. Control groups included mice immunized with saline, rabbit 
IgG obtained before Id injection (pre-IgG), and anti-Id directed against human 
anti-HBsAg,  which had  been raised by methods similar  to those described for 
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phamide (50  mg/kg  body weight)  2  d  before the  tumor inoculum.  Cyclophos- 
phamide treatment at this dose selectively destroys T  suppressor cells (51),  and 
the  role of this subset  of T  cells in  tumor  immunity has been  documented  for 
several systems (19,  20,  52-55).  Studies have also indicated that both the amino 
and carboxyl portions of T-Ag are exposed on the surface of transformed cells 
(37,  56-59).  For this reason,  we thought  that a  pool of the  two anti-T-Ag Id, 
recognizing both the amino and carboxyl determinants of T-Ag might be more 
effective in inducing tumor immunity. Of the nine groups of mice injected with 
anti-Id or control antibodies and  challenged  with  SV40-transformed cells,  only 
the group receiving a pool of anti-419 and anti-405  Id showed any reduction  of 
tumor size (Table  IV).  All  tumors induced  in each  mouse were measured with 
calipers 27 d after the SV40 tumor cell challenge, and the diameter was recorded. 
The mean tumor diameter of eight mice treated with pooled anti-419 and anti- 
405  Id  was  12.9  mm.  This  value  was compared  with  a  range  of mean  tumor 
diameters of 20-30  mm for the other eight treated groups of mice. The range 
of individual  tumor  diameters  for the  64  mice was  20-32  mm.  In  the  pooled 
anti-SV40  T-Ag Id-treated mice, two out of eight failed to develop any visible 
signs of tumors, and three others showed a  reduction  in tumor size (9-17  mm) 
compared with  the  other  treatment  groups.  To ensure  that  the  two  mice that 
failed to develop any tumors  had  indeed  received SV40-transformed  cells,  the 
mice were  bled  40  d  after  tumor  challenge,  and  the  sera  were  examined  for 
antibody activity against  SV40  T-Ag.  Both sera were positive for anti-T-Ag by 
immunofluorescence,  indicating  that  these  two  mice  had  received  the  tumor 
challenge. Cyclophosphamide had no effect on tumor growth, since no difference 
in the mean tumor diameter was observed between this treatment group of mice 
and controls. Assuming that cyclophosphamide treatment abolished T  suppressor 
cell activity, these data  suggest that  T  suppressor cells may have no detectable 
TABLE  IV 
Effect of Anti-ld Immunization on In Vivo SV40 Tumor Formation 
Treatment  Mean tumor diameter 
mm 
Anti-405 Id  22.4 + 0.51 
Anti-419 Id  24.2 + 0.76 
Anti-T-Ag Id (pool)*  12.9 + 2.33 
Anti-421 Id  27.2 +  1.41 
Anti-HD 200 Id  24.4 + 2.12 
Cyclophosphamide  ~  21.6 + 0.46 
Saline  20.4 + 0.79 
Pre lgG  23.0 4- 2.10 
Anti-ld (HBsAg)  29.6 +  1.71 
Each group of eight mice received three intraperitoneal  injections 10 d 
apart, and  were  challenged  with SV40-transformed  cells, subcutane- 
ously,  7  d  after  the  final injections.  Tumors were  measured  using 
calipers, 27  d after tumor inoculation.  Data are mean diameters,  in 
millimeters _SEM. 
* Consists of a pool of 25 ug each of affinity-purified anti-405 Id and anti- 
419 Id, 
* 50 mg/kg body weight was given intraperitoneally  2 d before tumor 
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effect on in vivo SV40 tumor immunity. This is in contrast to a previous study 
(60)  where cyclophosphamide treatment was reported to abolish suppressor T 
cell activity, thus augmenting the cell-mediated cytotoxicity  against SV40 tumors. 
Our study differs in that we measured in vivo SV40 tumor induction, whereas 
the previous  report  measured  the  in  vitro  response  to  SV40-induced  tumors 
using a  ~Cr-release assay to determine cytotoxicity. In other systems (19,  20), 
selective elimination of T  suppressor cells has resulted in either an inhibition of 
in  vivo  tumor  formation  or  suppression  of tumor  rejection.  In  addition,  it 
appeared that anti-Id directed against Id with specificity for both the carboxyl 
and amino determinants of SV40 T-Ag together could partially suppress in vivo 
tumor formation.  However, anti-Id directed to either the  carboxyl or amino 
portions of T-Ag by themselves had no effect. Also, anti-Id directed against p53 
did not appear to suppress in vivo tumor formation. At that point we did not 
know whether a pool of the two anti-Id for p53  would have an effect on tumor 
immunity. 
In  the  next  set  of experiments,  we  decided  to  repeat  the  in  vivo  tumor 
immunity induced by anti-SV40 T-Ag Id using intraperitoneal injections of an 
SV40-transformed mouse cell line (mKSA) that grows in the ascites form, using 
survival time as a  parameter of immunity. The SV40-transformed tumor cell 
line was titrated in order to give a dose of transformed cells that resulted in no 
survivors in untreated mice 21  d after injection. In addition, we also decided to 
examine what effects p53 and T-Ag Id injection had on the induction of SV40 
tumor  immunity.  Previous  investigators  (21)  had  implicated  in  vivo  anti-Id 
production induced by Id immunization for protection or reduction of tumor 
growth.  16  groups  of  10  mice  each  were  injected  with  Id,  anti-Id,  control 
antibodies, cyclophosphamide, saline, or SV40 before tumor challenge. Injection 
of mice with SV40  does not result in tumor formation, but provides immunity 
to subsequent challenge with SV40-transformed cells.  The mean survival time 
for  each  treatment  group  of mice  was  determined,  and  the  results  of this 
experiment are  shown in  Table  V.  The  mean survival time for all  treatment 
groups except for mice receiving the anti-T-Ag Id pool, SV40, or the SV40 T- 
Ag Id (pool) ranged from  18.6 to 21.7  d.  Mice treated with the anti-T-Ag Id 
pool or SV40  had mean survival times of 27.4 and 34.6 d, respectively. Based 
on  the  two-tailed student's t  test,  these  two  groups  of mice  had  significantly 
higher mean survival times, compared with 13 other treatment groups (P <0.05, 
anti-T-Ag Id pool; P  <0.001  SV40).  These results were in agreement with the 
above observations, where tumor induction was determined by the size  of the 
tumor. The anti-T-Ag Id pool suppressed the in vivo formation of tumors in 
mice, whereas cyclophosphamide used at a dose to selectively abolish suppressor 
T  cell  activity, or  individual anti-SV40  T-Ag and  p53  Id  had  no  effect.  In 
addition, Id preparations purified on anti-Id-containing affinity columns admin- 
istered both individually  and as a pool, and an anti-p53 Id pool had no statistically 
significant effect on SV40  tumor induction. However, the T-Ag Id pool had a 
longer mean survival time compared with other treatment groups (23.2 vs. 21.7 
and 10 d). 
It  is  noteworthy that  three  out  of the  10  anti-T-Ag  Id  pool-treated mice 
failed to develop tumors, and three others survived longer than any of the  140 1442  ANTIIDIOTYPES MODULATE TUMOR  FORMATION 
TABLE  V 
Effects of Various Id and Anti-Id Treatments on In Vivo SV40 Tumor 
Formation 
Number of 
survivors in  Mean survival 
Treatment  groups of  time* 
ten mice 
each 
d 
Anti-Id (405)  0  18.6 -Z-_ 0.65 
Anti-ld (419)  0  20.1 +  1.38 
Anti-T-Ag Id (pool)  3  27.4 -+ 2.55* 
Anti-ld (421)  0  19.0 +- 0.56 
Anti-ld (HD200)  0  19.4 _  0.59 
Anti-p53  Id (pool)  0  19.1 + 0.61 
405 Id  0  19.5 +  1.17 
419 Id  0  21.7 + 0.73 
T-Ag Id (pool)  0  23.2 -+ 0.78 
421  ld  0  20.4 -  0.80 
HD 200 ld  0  19.4 ___ 0.59 
p53  Id (pool)  0  19.2 + 0.72 
SV40 §  7  34.6 _+  1.54 II 
Cyclophosphamide  0  18.9 -  0.52 
Saline  0  21.4 + 0.86 
Anti-Id (HBsAg)  0  18.7 _  0.54 
Each group of 10  mice received three intraperitoneal injections,  each 
containing 50 #g of alum-prec~itated antibodies  10 d apart. The mice 
were then challenged with  10°SV40-transformed cells (mKSA) intra- 
peritoneally 7 d  after the  final  injections.  50  mg/kg body  weight of 
cyclophosphamide  was given intraperitoneally 2 d before tumor inocula- 
tion.  The day of death was determined for each mouse. 
* To aid calculations, the last death observed in the anti-T-Ag Id pool and 
SV40  treatment  groups was  37  d  after tumor inoculation.  Mice that 
survived tmnor challenge were arbitrarily given a survival time of 37 d. 
Mean survival time _+SEM. 
* Based on the two-tailed student's t test; P <0.05. 
Mice  received  l0  s  mKSA  SV40-transformed  cells  7 d  before tumor 
challenge. 
II Based on the two-tailed student's t test; P <0.001. 
mice receiving the  14  different treatments  that  resulted in no significant reduc- 
tion in tumor  growth. Thus, 4  out of 10 of the anti-T-Ag  Id pool-treated  mice 
showed  no  apparent  reduction  of  SV40  tumor  growth.  Similar  results  were 
obtained  when  tumor  size  was  measured,  with  three  out  of  the  eight  mice 
receiving anti-T-Ag  Id  pool  showing  no  reduction  in  tumor  size.  These  data 
suggest  that  anti-Id  preparations  that  recognize both  the  amino  and  carboxyl 
determinants  of SV40  T-Ag  have  some  role  in  suppressing  tumor  formation. 
However, these putative Id networks induced by anti-Id injection do not appear 
to  be  universally  active  in  suppression  of  tumor  formation  in  all  mice.  The 
injection of SV40 should confer protection against challenge with a  tumorigenic 
dose  of  SV40-transformed  cells.  Indeed,  7  of  10  mice  given  SV40  before 
challenge survived with  no  apparent  tumor  formation.  The  reasons  for tumor 
development resulting in  death  in the other three mice from this group are not KENNEDY  ET  AL.  1443 
known.  Note that,  in the calculations of mean survival time, mice that survived 
tumor challenge in the anti-Id (pool) and SV40 treatment groups were arbitrarily 
given 37 d  as their survival time to aid in the calculations.  This represented the 
last  day of death  observed  for  mice  in  both  treatment  groups.  This  arbitrary 
assignment of 37 d  for survival time resulted in a smaller value for mean survival 
time; however, the values obtained  were still significantly different  from other 
treatment groups. 
Induction  of an  Ab-3  (Anti-anti-Id)  that  Lacks  Anti-T-Ag  Activity.  Previous 
studies  (5-9,  11)  have  demonstrated  that  anti-Id  may mimic or  represent  the 
internal image of the antigen and induce an in vivo antiantigen response.  In this 
light,  the  ability of the  anti-Id  pool  to  mimic T-Ag and  induce  an  anti-T-Ag 
response capable of suppressing tumor formation was examined.  Mouse serum 
was obtained from anti-Id-injected  mice 7  d  after the third  immunization,  and 
assayed for anti-T-Ag activity by both immunofluorescence and radioimmuno- 
precipitation.  No  anti-T-Ag  activity  was  found  in  any of these  sera  (data  not 
shown).  In  addition,  the  ability  of these  sera  to  inhibit  the  various  Id-anti-Id 
reactions  was also analyzed.  The  data  presented  in  Table  VI  demonstrate  the 
ability of sera obtained from anti-Id-treated mice to inhibit the different Id-anti- 
Id  reactions.  Sera  from  four  anti-405  Id-treated  mice  inhibited  the  405  Id- 
anti-405  Id reaction  36-47%,  whereas the same sera inhibited  the other three 
Id-anti-Id reactions by <8%.  Only sera from anti-421  Id-injected mice failed 
to inhibit (6-11%) its respective Id-anti-Id reaction significantly when compared 
with  the  other  three  Id-anti-Id  reactions.  It  was  interesting  that  serum  from 
mice immunized with the anti-T-Ag Id pool inhibited both the 405 Id- and 419 
Id-anti-Id reactions, yet no anti-T-Ag activity could be demonstrated. Based on 
the 405 and 419 Id inhibition curves shown in Fig. 2, and the levels of inhibition 
obtained with the mouse sera diluted  1 : 10, the approximate amounts of 405 and 
419  Id  present  in  these  mouse  sera  were  120  and  80  ng,  respectively.  This 
quantity  of  405  and  419  antibody  is  well  within  the  range  of the  limits  of 
detecting  anti-T-Ag activity by both immunofluorescence and  immunoprecipi- 
tation.  Therefore,  the  antibody  induced  by anti-Id injection  that  is capable of 
TABLE VI 
Induction of an Anti-anti-Id  (Ab-3) Response in Mice Receiving Anti-Id 
HD 200  405 Id-anti-  419 ld-  421 ld-  Treatment  Id-anti-H D  405  anti-419  anti-421  2OO 
% 
Anti-405 Id  36-47"  0-7  0-4  0-3 
Anti-419 Id  4-8  29-44  2-6  1-5 
Anti-T-ag Id (pool)*  34-45  31-46  0-4  1-5 
Anti-421 Id  4-7  1-6  6-11  2-7 
Anti-HD 200 Id  I-4  2-7  3-6  28-46 
Each group of four mice received three intraperitoneal  injections 10 d apart. 
Serum was obtained 7 d after the final injections. 
The range of percent inhibition values determined  using a  1:10 dilution of 
serum as an inhibitor of the various Id-anti-ld reactions. 
Consists of a pool of 25 #g each of affinity-purified anti-405 Id and anti-419 
Id. 1444  ANTIIDIOTYPES  MODULATE  TUMOR  FORMATION 
inhibiting the Id-anti-Id reactions must be an anti-anti-Id (Ab-3)  response that 
does not represent a true internal image and lacks anti-T-Ag activity. 
This  report  characterizes  four  private  or  unique  Id  associated  with  mAb 
directed against SV40 T-Ag and p53, using anti-Id produced in rabbits. These 
Id determinants were associated, in part, with the antibody-combining site, since 
either  purified  T-Ag  or  T-Ag-p53  complexes  specifically inhibited  the  four 
Id-anti-Id reactions. The specificity of these reactions was demonstrated by the 
ability of both T-Ag and T-Ag-p53 complexes to inhibit the 405  Id-anti-405 
Id and 419  Id-anti-419 Id reactions, whereas only the preparations containing 
T-Ag-p53 complexes inhibited the p53 monoclonal Id-anti-Id reactions. These 
various anti-Id were then used in vivo in an attempt to modulate tumor formation 
in BALB/c mice subsequently challenged with SV40-transformed cells. 
Previous  studies  (28-31,  reviewed  in  32)  have  demonstrated that  either  a 
subtumorigenic dose of SV40-transformed cells,  SV40 alone, or purified T-Ag 
given  before  tumor  cell  challenge  could  completely suppress  in  vivo  tumor 
formation. Alternatively, studies with viral Ag systems have shown that anti-Id 
can behave as the internal image, and induce an antiviral response (5-9,  11, 61, 
62). The first of such reports, by Urbain et al. (61),  characterized the induction 
of an anti-tobacco mosaic virus capsid protein response in mice injected with 
anti-Id alone.  The  original postulate of this  report  was  that  anti-Id directed 
against  mAb  to  SV40  T-Ag  may represent  the  internal  image  of T-Ag and 
induce in vivo tumor immunity. Thus, we used the antMd characterized herein 
to modulate the immune response to SV40-transformed cells. 
In our initial experiments, anti-Id to either SV40  T-Ag or p53  individually 
had no effect on in vivo SV40 tumor formation. Other studies (37, 56-59) had 
demonstrated that  both  the  amino  and  carboxyl termini  of SV40  T-Ag are 
exposed on tbe surface of transformed cells, and both may play a role in tumor 
immunity. Because mAb 405 and 419 bind to the carboxyl and amino portions 
of SV40 T-Ag, respectively, we examined what effects a pool of these two anti- 
Id had on in vivo tumor formation. In two different sets of experiments, only 
this pool of the two anti-Id directed against T-Ag was capable of suppressing the 
formation of tumors by  SV40-transformed cells.  Not  all  mice  in  the  anti-Id 
pool-treated group showed suppression of tumor growth. In the first experiment, 
two of a group of eight mice failed to develop any tumors, and three other mice 
showed a  reduction in tumor size  compared with groups of mice treated with 
control antibodies. In the second experiment, of 10  mice treated with anti-Id 
(pool),  3  failed  to  demonstrate  any  tumor  formation,  and  3  others  showed 
increased  survival  times  compared  with  control  groups.  Therefore,  in  two 
different experiments,  anti-Id pool  treatment before  SV40  tumor challenge 
suppressed or partially suppressed tumor formation in 62.5%  and 60%  of the 
immunized mice.  Why anti-Id  treatment affected only certain  mice  within  a 
given strain is not known. However, protection was not reproducibly observed 
for each mouse. In addition, serum from each mouse that did not develop tumors 
was assayed for anti-T-Ag activity by indirect immunofluorescence to ascertain 
whether these  mice had  been  successfully challenged with  SV40-transformed 
cells.  All five mice developed an anti-T-Ag response. 
The  in  vivo suppression  of tumor growth by the  injection of anti-Id or  Id KENNEDY  ET  AL.  1445 
generated to a given tumor Ag has been shown in other systems (17-19, 21,63- 
70). The  mechanisms  of this suppression  represented  the production  of either 
anti-anti-Id  or anti-Id that was capable of stimulating or suppressing effector or 
inducer cells bearing anti-Id or Id receptors (17-19,  21, 63-70). We attempted 
to determine and postulate the potential mechanism of anti-Id-induced suppres- 
sion in the SV40 tumor system. 
The  role  of T  suppressor  cells has  been  demonstrated  in  the  induction  or 
suppression of tumor immunity in several systems (19, 20,  52-55,  63-65).  We 
used cyclophosphamide  (50  mg/kg  body weight)  to selectively destroy T  sup- 
pressor cells (51) before SV40 tumor challenge,  and found that this treatment 
had no effect on in vivo tumor growth. Thus, T  suppressor cells did not appear 
to have a major role in the mechanism of SV40 tumor immunity. However, this 
does not  rule  out the  possibility that  T  suppressor  cells bearing  Id or anti-Id 
receptors may have a role in the anti-Id-induced  suppression of tumor growth. 
Next, we studied whether the anti-Id represented the internal image of SV40 T- 
Ag and  induced an anti-T-Ag  response.  No detectable anti-T-Ag  activity was 
found  in  the  serum  of anti-Id-treated  mice.  However,  it  is  possible that  the 
polyclonai anti-Id preparations have a very minor internal image component that 
cannot  be  detected  in  our  assay  systems.  Together,  these  data  indicate  that 
traditional  immunization  with  SV40  T-Ag  was  more  effective than  anti-Id  in 
producing tumor immunity. The failure of Id to provide protection is consistent 
with earlier evidence (71, 72), and that effector T  cells were not analyzed in this 
study but may well play a  central  role in the anti-Id-induced  immunity via the 
induction of regulatory idiotopes. 
The  studies  reported  herein  demonstrate  that  Id networks  may have  some 
role in SV40 tumor immunity. An interesting mechanism that supports the data 
on tumor suppression  reported  in  this manuscript  involves the induction  of an 
immune response to regulatory idiotopes. Further characterization of the poten- 
tial  Id  networks  produced  during  the  course  of SV40  tumor  growth  will  be 
required before the mechanisms that occur during this complex immunological 
event will be unraveled. 
Summary 
This study characterizes four private idiotypes (Id) associated with monoclonal 
antibodies  (mAb)  to  simian  virus  40  (SV40)  tumor  antigen  (T-Ag),  and  to  a 
cellular  protein,  p53.  Anti-Id  recognized  Id  determinants  associated with  the 
antibody-combining site. BALB/c mice receiving a pool ofanti-Id directed against 
mAb recognizing distinct amino and carboxyl terminal epitopes of T-Ag before 
receiving a  tumorigenic  dose of SV40-transformed  cells showed suppression of 
tumor  formation.  Serum  obtained  from  these  mice  before  tumor  challenge 
contained anti-anti-Id that failed to bind T-Ag. These data support the potential 
role of regulatory idiotopes in tumor immunity. 
Received for publication  24January 1985 and in revised form 8 March 1985. 
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